Literature DB >> 7903045

Summary of the National Institutes of Health workshop on primary human immunodeficiency virus type 1 infection.

M T Niu1, J A Jermano, P Reichelderfer, S M Schnittman.   

Abstract

A Workshop on primary human immunodeficiency virus type 1 (HIV-1) infection sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and the Office of AIDS Research (OAR) of the National Institutes of Health (NIH) was held February 25-26, 1993 in Bethesda, Maryland. The major goals of this scientific meeting were to bring together researchers and infectious disease specialists who have expertise in primary HIV-1 infection (PHI) to review the pathogenesis of PHI, the treatment experience of PHI in humans and of early retroviral infection in animal models, and to devise theoretical and operational strategies for future clinical trials relating to therapeutic intervention of PHI. The proceedings of this workshop are timely and serve to further the development of innovative strategies for the treatment of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7903045     DOI: 10.1089/aid.1993.9.913

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  4 in total

1.  Early pathogenesis of transmucosal feline immunodeficiency virus infection.

Authors:  Leslie A Obert; Edward A Hoover
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 x 10(6)/l, AIDS, and death from AIDS?

Authors:  S Lindbäck; C Broström; A Karlsson; H Gaines
Journal:  BMJ       Date:  1994-12-10

3.  Dynamics of viral replication in infants with vertically acquired human immunodeficiency virus type 1 infection.

Authors:  A De Rossi; S Masiero; C Giaquinto; E Ruga; M Comar; M Giacca; L Chieco-Bianchi
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

4.  Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen.

Authors:  M J McElrath; L Corey; P D Greenberg; T J Matthews; D C Montefiori; L Rowen; L Hood; J I Mullins
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.